Pharma BD Deal Intelligence
Takeda completed the sale of Xiidra to Novartis to accelerate deleveraging following its $62 billion acquisition of Shire, transferring approximately…
Novartis completed the divestment of its front-of-eye ophthalmology assets (including Xiidra/lifitegrast and SAF312/libvatrep) to Bausch + Lomb on September…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis acquired global rights to Xiidra (lifitegrast), an approved treatment for dry eye disease, from Takeda (which inherited the asset from its Shire acquisition). Novartis paid $3.4B upfront plus up to $1.9B in milestones. This was part of Takeda's post-Shire divestiture strategy to reduce debt.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Takeda Pharmaceutical Company Ltd. (this deal) | 2019 | $5.3B | 33 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2019 deals · Novartis AG deals · Neurology deals